Biocon Becomes Latest Stelara Challenger In US

Indian Biosimilars Giant Receives FDA Approval For Yesintek Version Of Ustekinumab

 
• By Dave Wallace
  
Biocon is one of several US Stelara challengers lining up to launch in 2025 (Shutterstock)

More from Biosimilars

More from Generics Bulletin